CARNA BIOSCIENCES

News Release

November 5, 2026
Carna Biosciences, Inc.

Carna announces acceptance of two posters on docirbrutinib for presentation at the 68th ASH Annual Meeting

Carna Biosciences, a clinical-stage biopharmaceutical company focusing on the discovery and development of innovative therapies to treat serious unmet medical needs, today announces that two posters on docirbrutinib (AS-1763) will be presented at the 68th American Society of Hematology (ASH) Annual Meeting & Exposition.

Docirbrutinib, an investigational small molecule drug designed to non-covalently inhibit Bruton's tyrosine kinase (BTK) in a highly selective manner, is currently under development for the treatment of patients with chronic lymphocytic leukemia (CLL) and other B-cell malignancies who have developed resistance or are intolerant to at least two prior lines of systemic therapy including existing covalent/non-covalent BTK inhibitors. The latest clinical data from the ongoing Phase 1b trial of docirbrutinib will be presented separately by Prof. Nitin Jain, MD, Department of Leukemia, The University of Texas MD Anderson Cancer Center and Prof. Nirav Shah, MD, Division of Hematology/Oncology, Medical College of Wisconsin. Both presentations will be co-authored by the principal investigators from all trial sites. The ASH Annual Meeting and Exposition will take place December 12-15, 2026, in New Orleans, Louisiana.

Presentation Details

Publication Number: 3878

Poster title:	Docirbrutinib, a non-covalent pan-mutant Bruton's tyrosine kinase (BTK) inhibitor, in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Phase 1b study update
Session:	642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II
Session date:	December 13, 2026
Presenter:	Nitin Jain[1], Catherine C. Coombs[2], Nirav Shah[3], Seung Tae Lee[4], Jonathan S. Goldberg[5], Sunil Babu[6], John Nemunaitis[7], Danielle Brander[8], Andrew Gillis-Smith[9], Shuo Ma[10], Jacqueline Barrientos[11], Koji Yoshida[12], Masaaki Sawa[12], Kyoko Miyamoto[13], Akinori Arimura[13], William Wierda[1], Varsha Gandhi[14], Javier Pinilla-Ibarz[15]

[1] The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX, United States, [2] University of California Irvine Health, Division of Hematology/Oncology, Irvine, CA, United States, [3] Medical College of Wisconsin, Division of Hematology/Oncology, Milwaukee, WI, United States, [4] University of Maryland Medical Center, Greenebaum Comprehensive Cancer, Baltimore, MD, United States, [5] Optum Medical Care, Department of Hematology and Oncology, Mount Kisco, NY, United States, [6] American Oncology Partners, Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN, United States, [7] Taylor Cancer Research Center, Maumee, OH, United States, [8] Duke Cancer Institute, Division

of Hematologic Malignancies and Cellular Therapy, Durham, NC, United States, [9] University of Massachusetts Memorial Medical Center, Hematology/Oncology, Worcester, MA, United States, [10] Robert H. Lurie Comprehensive Cancer Center, Northwestern Memorial Hospital, Hematology/Oncology, Chicago, IL, United States, [11] Mount Sinai Medical Center, Miami Beach, FL, United States, [12] Carna Biosciences, Inc., Kobe, Japan, [13] CarnaBio USA, Inc., South San Francisco, CA, United States, [14] The University of Texas MD Anderson Cancer Center, Department of Translational Molecular Pathology, Houston, TX, United States, [15] Moffitt Cancer Center, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States

The abstract is now available at: https://onlineprogram.hematology.org/paper-details.aspx?pid=683330

Publication Number: 1815

Poster title:	Docirbrutinib, a non-covalent pan-mutant Bruton's tyrosine kinase (BTK) inhibitor, in patients with previously treated mantle cell lymphoma, Waldenström macroglobulinemia, and other B-cell malignancies: Phase 1b study update
Session:	623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I
Session date:	December 12, 2026
Presenter:	Nirav Shah[1], Jonathan S. Goldberg[2], John Nemunaitis[3], Catherine C. Coombs[4], Jacqueline Barrientos[5], Danielle Brander[6], Andrew Gillis-Smith[7], Sunil Babu[8], Seung Tae Lee[9], Shuo Ma[10], Koji Yoshida[11], Masaaki Sawa[11], Kyoko Miyamoto[12], Akinori Arimura[12], Nitin Jain[13], Javier Pinilla-Ibarz[14]

[1] Medical College of Wisconsin, Division of Hematology/Oncology, Milwaukee, WI, United States, [2] Optum Medical Care, Department of Hematology and Oncology, Mount Kisco, NY, United States, [3] Taylor Cancer Research Center, Maumee, OH, United States, [4] University of California Irvine Health, Division of Hematology/Oncology, Irvine, CA, United States, [5] Mount Sinai Medical Center, Miami Beach, FL, United States, [6] Duke Cancer Institute, Division of Hematologic Malignancies and Cellular Therapy, Durham, NC, United States, [7] University of Massachusetts Memorial Medical Center, Hematology/Oncology, Worcester, MA, United States, [8] American Oncology Partners, Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN, United States, [9] University of Maryland Medical Center, Greenebaum Comprehensive Cancer,Baltimore, MD, United States, [10] Robert H. Lurie Comprehensive Cancer Center, Northwestern Memorial Hospital, Hematology/Oncology, Chicago, IL, United States, [11] Carna Biosciences, Inc., Kobe, Japan, [12] CarnaBio USA, Inc., South San Francisco, CA, United States, [13] The University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX, United States, [14] Moffitt Cancer Center, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States

The abstract is now available at: https://onlineprogram.hematology.org/paper-details.aspx?pid=693342

About docirbrutinib (AS-1763)

Docirbrutinib is a highly selective, orally bioavailable, non-covalent inhibitor of both the wild type and mutant BTKs for the treatment of CLL and other B cell malignancies. Covalent BTK inhibitors including ibrutinib are key therapeutic options for patients with B cell malignancies. However, patients are reported to develop resistance during the treatment due to substitution of cysteine residue at 481 position with serine (C481S

- 2 -mutation) in BTK, which reduces the efficacy of the covalent BTK inhibitors. In addition, the emergence of other types of resistance mutations to non-covalent BTK inhibitor, recently approved pirtobrutinib, has been reported. Docirbrutinib potently inhibited both wild type and those mutant BTKs, strongly suggesting that docirbrutinib will be a new therapeutic option for treating patients with B cell malignancies both having wild type and resistance mutations in BTK. Carna is advancing development of docirbrutinib as a nextgeneration BTK inhibitor. The Phase 1b study of docirbrutinib is being conducted in the U.S. and dosing in the dose expansion part is ongoing (NCT05602363).

Contact:
Corporate Planning
Carna Biosciences, Inc.
TEL: +81-78-302-7039
https://www.carnabio.com/english/